跳至主要内容
临床试验/NCT03699657
NCT03699657已完成不适用

Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode

Seoul National University Hospital2 个研究点 分布在 2 个国家目标入组 86 人开始时间: 2014年12月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
86
试验地点
2
主要终点
Minimum diameter of ablative zone

研究概览

简要总结

This study was conducted to prospectively compare the efficacy, safety and mid-term outcomes of dual-switching monopolar (DSM) radiofrequency ablation (RFA) with those of conventional single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC).

详细描述

Recently, dual switching monopolar RFA (DSM-RFA) was developed to enhance further the efficiency of the single switching monopolar RFA (SSM-RFA) in creating ablation zone; Yoon et al. reported that DSM-RFA allowed significantly greater RF energy delivery to target tissue per given time, and then, created significantly larger ablation zone than the SSM-RFA in ex vivo and in vivo animal experiments. A retrospective comparative study by Choi et al. reported that the DSM-RFA created significantly larger ablation volume than, but seemed to show similar LTP rate to the SSM-RFA. Still, whether the physical differences between SSM-RFA and DSM-RFA translate into better clinical outcomes remains an open question. Regarding that the choice of equipment is an essential factor to consider in planning image-guided tumor ablation procedure, we thought that the prospective comparison between DSM-RFA and the SSM-RFA would be helpful for improving results of RFA.

Therefore, the purpose of this study was to prospectively compare the efficacy, safety and mid-term outcomes of DSM-RFA with those of conventional SSM-RFA in the treatment of HCC.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with HCC (>= 1.5cm and < 5cm in maximal diameter) according to AASLD guideline or LI-RADS on MDCT or liver MRI within 60 days before RFA
  • no history of previous locoregional treatment

排除标准

  • more than three HCC nodules
  • tumors abutting to the central portal vein or hepatic vein with a diameter > 5 mm
  • Child-Pugh class C
  • tumors with major vascular invasion
  • extrahepatic metastasis
  • severe coagulopathy (platelet cell count of less than 50,000 cells/mm3 or INR prolongation of more than 50 %)

结局指标

主要结局

Minimum diameter of ablative zone

时间窗: 7 days after RFA

Minimum diameter of ablative zone on post-RFA CT or MRI in a mm.

次要结局

  • 1-year local tumor progression (LTP)(12 months after RFA)
  • Technical success rate(1 month)
  • IDR rate(24 months after RFA)
  • EM rate(24 months after RFA)
  • 2-year LTP(24 months after RFA)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeong Min Lee

Professor

Seoul National University Hospital

研究点 (2)

Loading locations...

相似试验

Dual and Single Switching Monopolar RFA Using... | 临床试验